Methods for identifying and validating selective anti-cancer stem cell agents

Patent metadata

Field	Value
Publication number	US-9566282-B2
Application number	US-201213605609-A
Country	US
Kind code	B2
Filing date	Sep 6, 2012
Priority date	Feb 28, 2011
Publication date	Feb 14, 2017
Grant date	Feb 14, 2017

Abstract

Described are methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a dopamine receptor (DR) antagonist. The DR antagonist may be a phenothiazine derivative, such as thioridazine or chlorpromazine. Optionally, the cancer is acute myeloid leukemia. Also described are methods for identifying subjects with cancer, methods for providing a prognosis for a subjects with cancer and methods for identifying subjects likely to be responsive to therapy with DR receptor antagonists. Methods for identifying cancer stem cells and chemotherapeutic compounds that are DR receptor antagonists as also provided. Also described are methods for the identification and validation of agents that target cancer stem cells.

First claim

The invention claimed is:

1. A method for identifying and validating a test agent as a selective anti-cancer stem cell agent, the method comprising:
i) contacting one or more variant neoplastic stem cells with the test agent and one or more normal stem cells with the test agent,
wherein said variant neoplastic stem cells are transformed human Pluripotent Stem Cells or transformed induced Pluripotent Stem Cells characterized as having at least one property selected from
an ability to differentiate into more than one cell type without requiring Oct4 for self-renewal or survival,
an ability to co-express FGFR1 and IGFR1,
an ability to maintain an undifferentiated state in culture absent the presence of fibroblast growth factor (bFGF),
an ability to maintain the expression of SSEA3 in the absence of bFGF, and
a requirement of the presence of Nanog for self-renewal and cell survival;

ii) detecting a change in cell count of the variant neoplastic stem cells in response to the test agent, and detecting a change in cell count of the normal stem cells in response to the test agent; and
iii) identifying the test agent as a selective anti-cancer stem cell agent if contact with the test agent induces a decrease in cell count of the variant neoplastic stem cells without inducing a comparable decrease in the normal stem cells;
wherein the variant neoplastic stem cells are seeded in a first receptacle at about 3000 to 7000 cells per receptacle and the normal stem cells are seeded in a second receptacle at about 8000 to 12000 cells per receptacle.

2. The method of claim 1 , further comprising, contacting the variant neoplastic stem cells and the normal stem cells with the test agent at a plurality of test concentrations and detecting a change in cell count for the one or more variant neoplastic stem cells and for the normal stem cells at the plurality of test concentrations.

3. The method of claim 2 , wherein the plurality of test concentrations varies by at least about 3, 4 or 5 orders of magnitude.

4. The method of claim 2 , wherein the plurality of concentrations varies from about 10 nM to about 20 μM.

5. The method of claim 2 , wherein the plurality of test concentrations comprises at least an 8 point dilution series.

6. The method of claim 2 , wherein step iii) comprises comparing a dose-response curve for the change in cell count of the variant neoplastic stem cells in response to contact with the test agent at the plurality of test concentrations to a dose-response curve for the change in cell count of the normal stem cells in response to contact with the test agent at the plurality of test concentrations.

7. The method of claim 6 , further comprising determining for the test agent a half maximal effective concentration (EC50) value for decrease in cell count for the variant neoplastic stem cells, and an EC50 value for decrease in cell count in the normal stem cells.

8. The method of claim 7 , further comprising determining a ratio of the EC50 value for decrease in cell count for the normal stem cells relative to the EC50 value for decrease in cell count for the variant neoplastic stem cells.

9. The method of claim 8 , wherein step iii) comprises identifying the test agent as a selective anti-cancer stem cell agent if the ratio of the EC50 values is greater than 3.

10. The method of claim 1 , wherein the variant neoplastic stem cells are seeded at about 4000 to 6000 cells per receptacle.

11. The method of claim 1 , wherein the normal stem cells are seeded at about 9000 to 11000 cells per receptacle.

12. The method of claim 1 , wherein the change in cell count for the variant neoplastic stem cells is detected between about 48 hours and 96 hours after contacting the cells with the test agent, and the change in cell count for the normal stem cells is detected between about 4 days and 6 days after contacting the cells with the test agent.

13. The method of claim 1 , further comprising screening the test agent identified as a selective anti-cancer stem cell agent for activity on a cancer cell line derived from a subject with cancer.

14. The method of claim 13 , wherein the cancer cell line is a leukemic cell line.

15. The method of claim 1 , further comprising prior to step i) screening one or more agents to identify one or more test agents that induce loss of pluripotency and a decrease in cell count of variant neoplastic stem cells.

16. The method of claim 15 , comprising prior to step i) contacting the variant neoplastic stem cells with the agent, detecting a change in pluripotency and a change in cell count of the variant neoplastic stem cells in response to the agent and selecting an agent as the test agent if the agent induces a loss of pluripotency and a decrease in cell count of the variant neoplastic stem cells.

17. The method of claim 16 , wherein a plurality of agents are screened on a microtiter plate and identified as test agents based on a threshold standard deviation from the mean.

18. A two-stage method for identifying and validating an agent as a selective anti-cancer stem cell agent, the method comprising:
i) detecting a change in pluripotency and a change in cell count of variant neoplastic stem cells in response to contact with the agent and selecting an agent as a test agent if the agent induces a loss of pluripotency and/or a decrease in cell count of the variant neoplastic stem cells; and
ii) contacting one or more variant neoplastic stem cells with the test agent and contacting one or more normal stem cells with the test agent, detecting a change in cell count of the variant neoplastic stem cells in response to the test agent at a plurality of test concentrations,
detecting a change in cell count of the normal stem cells in response to the test agent at a plurality of test concentrations, and
identifying the test agent as a selective anti-cancer stem cell agent if the test agent induces a decrease in cell count of the variant neoplastic stem cells without inducing a comparable decrease in the normal stem cells;
wherein the variant neoplastic stem cells are transformed human Pluripotent Stem Cells or transformed induced Pluripotent Stem Cells characterized as having at least one property selected from
an ability to differentiate into more than one cell type without requiring Oct4 for self-renewal or survival,
an ability to co-express FGFR1 and IGFR1,
an ability to maintain an undifferentiated state in culture absent the presence of fibroblast growth factor (bFGF),
an ability to maintain the expression of SSEA3 in the absence of bFGF, and
a requirement of the presence of Nanog for self-renewal and cell survival; and

wherein the variant neoplastic stem cells are seeded in a first receptacle at about 3000 to 7000 cells per receptacle and the normal stem cells are seeded in a second receptacle at about 8000 to 12000 cells per receptacle.

19. The method of claim 18 , wherein the plurality of test concentrations varies by at least about 3, 4 or 5 orders of magnitude.

20. The method of claim 18 , wherein the plurality of concentrations varies from about 10 nM to about 10 μM.

21. The method of claim 18 , wherein the plurality of test concentrations comprises at least an 8 point dilution series.

22. The method of claim 18 , wherein step ii comprises comparing a dose-response curve for the change in cell count of the variant neoplastic stem cells in response to contact with the test agent at the plurality of test concentrations to a dose-response curve for th

Assignees

• Bhatia Mickie
• Collins Tony
• Sachlos Eleftherios
• Munoz Risueno Ruth
• Univ Mcmaster

Inventors

• Bhatia Mickie
• Collins Tony
• Sachlos Eleftherios
• Munoz Risueno Ruth

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• G01N2500/10

  involving cells · CPC title

• G01N2800/56

  Staging of a disease; Further complications associated with the disease · CPC title

• A61K31/5415 Primary

  ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam · CPC title